Review Papers Claim by Claim

Concise appraisal

The review Emerging HER2 Targeting Immunotherapy for Cholangiocarcinoma (DOI 10.32604/or.2025.065319) synthesizes literature on HER2 alterations in cholangiocarcinoma, current HER2 directed platforms (mAbs, ADCs, bispecifics, CARs), early clinical signals (eg zanidatamab, trastuzumab combinations), and the role of mouse and PDX models for preclinical translation; authors conclude HER2 is a promising target in a defined CCA subset but emphasize knowledge gaps including limited CCA-specific trial data and intratumoral heterogeneity Primary review article

Full evidence based review and critique

1 Key claims of the paper

• HER2 alterations occur in a clinically relevant subset of CCA and are enriched in liver fluke associated disease; alterations associate with poorer prognosis HER2 frequency and prognostic association in CCA
• Multiple HER2 targeting immunotherapy platforms (monoclonal antibodies, ADCs such as trastuzumab deruxtecan, biparatopic antibodies like zanidatamab, bispecific engagers, CAR platforms) are applicable or under study in HER2 altered CCA with encouraging early signals (ORR and DCR reported in phase 2/early trials) Clinical signals for HER2 agents in CCA
• Preclinical models including humanized and PDX mouse models are critical to resolve mechanism, resistance, and intratumoral heterogeneity before broad clinical adoption Role of preclinical models

2 Strengths

1. Comprehensive cross platform synthesis: clear survey of antibodies, ADCs, bispecifics, CAR approaches, radionuclide and nanobody strategies with mechanistic notes and clinical outcome summaries Comprehensive therapeutic coverage
2. Contextualization within CCA molecular subtypes: properly highlights liver fluke associated clusters and advises molecular testing (IHC/ISH/NGS/ctDNA) Testing recommendations
3. Balanced discussion of limitations and translational gaps, including intratumoral heterogeneity, TME immune suppression, and limited dedicated CCA trials

3 Weaknesses, gaps, and potential biases

• Evidence reliance and selection bias risk: the review is narrative and sources cited appear weighted toward promising agents and select phase 1/2 trials; absence of a systematic search or meta analytic weighting raises publication bias risk Narrative review design and bias risk
• Heterogeneity of HER2 definitions across studies: IHC scoring borrowed from breast/gastric cancers is used variably, and NGS copy number thresholds differ across trials — the review notes this but cannot resolve it, limiting comparability of reported ORR figures Assay heterogeneity in HER2 status
• Limited external validation and follow up data: early ORR and DCR from small cohorts are promising but likely inflated by selection and small sample sizes; longer PFS and OS data in CCA remain sparse Limitations of current clinical data
• Translatability concerns: preclinical models discussed (PDX, humanized mice) are necessary but their predictive value for multi-agent immunotherapy and ADC immune effects in a desmoplastic, hypovascular organ like the biliary tree is uncertain and requires empirical validation

4 Practical takeaways and recommendations

1. For clinical investigators: design prospective trials in molecularly defined HER2 altered CCA (predefine assay and amplification cutoffs, central pathology review, include ctDNA correlative arms) — the paper argues for these steps as critical to avoid cross trial heterogeneity Trial design recommendations
2. Preclinical priority experiments: compare ADCs versus biparatopic antibodies and bispecific engagers in matched PDX and humanized models with assessment of payload bystander effect, ADCC/ADCP, complement activation, and TME remodeling — the review highlights mechanisms that differ between platforms and should guide translational prioritization Mechanistic differences between platforms
3. Biomarker development: develop multiassay algorithms (IHC, ISH, NGS, ctDNA) and spatial profiling to quantify intratumoral heterogeneity and to predict which platform (ADC vs mAb vs CAR) is most likely effective for a given tumor

5 Where the paper could be stronger

• Provide systematic search methods and risk of bias table to quantify evidence quality across cited trials and preclinical studies (would increase reproducibility)
• Include pooled summary statistics or meta analytic synthesis where feasible (eg pooled ORR across HER2 selected CCA cohorts) rather than narrative point estimates to better represent uncertainty
• More explicit discussion of safety signals relevant to CCA patients (hepatic reserve, cholestasis, biliary sepsis risk) when using hepatically cleared ADCs or systemic immune modulators

6 Contradictions and blindspots

The review notes that ERBB2 altered CCA may do worse with PD-L1 blockade added to chemotherapy in one dataset (shorter OS trend with durvalumab plus gemcitabine/cisplatin), suggesting that combining ICIs blindly with HER2 agents is not necessarily beneficial and needs mechanistic justification and stratified testing rather than assumption of synergy ICI combination caution

7 Confidence and falsification

Current confidence that HER2 is a valid therapeutic target in a molecularly selected CCA subset is moderate: early ORR signals are encouraging but depend on small, selected cohorts; falsification would require adequately powered randomized evidence showing no benefit in objective endpoints when HER2 directed therapy is tested against standard of care in prospectively defined HER2 altered CCA populations — the paper acknowledges this empirical path forward Falsifiability statement

8 Recommended immediate next experiments

1. Head to head preclinical comparison in matched PDX models of T-Dxd, zanidatamab, and trastuzumab plus tucatinib assessing tumor growth inhibition, immune infiltration (CD8, Treg, macrophage polarization), and payload bystander activity
2. Prospective multicenter phase 2 biomarker driven trial: central HER2 testing with IHC+ISH and NGS, include ctDNA, stratify by homogenous versus heterogeneous HER2 expression, endpoints ORR, DoR, PFS, and translational correlatives (TME and resistance mechanisms)

9 Two brief critical quotations from the paper

"Focusing on HER2 expression could provide alternative strategies for the HER2 altered CCA cluster."

"Multiomics and appropriate preclinical animal models are pivotal to bridge basic research to clinical studies in CCA."

10 Tools to continue work

Note: This critique is grounded on the review article DOI 10.32604/or.2025.065319 and highlights the article conclusions, strengths, and limitations; claims above are directly tied to the article text and its presented trial summaries and translational recommendations Primary review article repeated